Hormones & endocrine · Protein hormone medicine
Also known as Genotropin, Norditropin, recombinant human growth hormone
Recombinant human growth hormone found in FDA-approved products for specific growth-hormone and growth-failure conditions.[1]
Human studies and labelled product evidence are available in specific contexts. This is not a ranking of suitability or a guarantee that every product or use has the same evidence.
Reviewed Jul 22, 2026 · U.S.-focused reference profile
Read the context, not only the compound name. Evidence and status can change with the form, route, population, and use. This profile does not assess individual suitability.
Orientation
Start with identity and research context. Similar names do not establish equivalent products or evidence.
Published research or product contexts. These are not personal indications.
Evidence can change with chemical form, formulation, route, ingredients, and manufacturing. A brand, salt, fragment, or cosmetic ingredient may not represent the same evidence.
What is known
Human studies and labelled product evidence are available in specific contexts. This is not a ranking of suitability or a guarantee that every product or use has the same evidence. This is a description, not a rating or recommendation.
Hormone-related and clinician-directed
Clinical trials and established use support product-specific indications for growth failure and documented growth-hormone deficiency. Evidence does not establish general anti-aging, athletic, or body-composition use.
Indications and device formulations vary by product. Long-term surveillance is important in treated populations, and approved somatropin is not evidence for products of uncertain identity or for enhancement use.
Source [1]Nonclinical pharmacology reflects growth-hormone receptor activity and informs product development. Mechanistic effects cannot establish net benefit outside studied clinical conditions.[1]
More human evidence does not automatically transfer to a different product, route, population, or purpose. Limited evidence does not prove no biological activity; it means the relevant clinical question is not established by the reviewed material.
What needs caution
Known published concerns and unanswered questions are kept separate so absence of evidence is never presented as reassurance.
Labeled risks include glucose intolerance, intracranial hypertension, fluid retention, slipped capital femoral epiphysis in growing patients, progression of scoliosis, pancreatitis, and risks in certain acute critical illnesses or active malignancy contexts.
The cited product label describes risks for a specific approved product and use. It is not a complete guide to every product or individual situation.Source [1]Indications and device formulations vary by product. Long-term surveillance is important in treated populations, and approved somatropin is not evidence for products of uncertain identity or for enhancement use.
The answer can change with the product, formulation, route, population, duration, and use being discussed.Source [1]Common effects, important warnings, product-quality concerns, and evidence gaps are different kinds of information. A risk in one product label may not apply to every formulation; an uncertainty proves neither safety nor harm.
Match the product
Form describes the specific product; route describes how it reaches the body. These are sourced descriptions, not instructions.
FDA-approved recombinant growth-hormone product for subcutaneous injection in defined labeled conditions.
Routes shown apply only to the named published or investigational formulation; they are not instructions for use.
U.S. product context
At least one FDA-approved product exists, but approval applies only to the named product, formulation, route, population, and use in its label.
Status applies to a product, formulation, route, population, and use. It does not apply to a name in the abstract.
Somatropin is FDA approved in multiple product-specific formulations for defined growth-hormone and growth-failure conditions.
Specific form or route not separately published in this record.View sourceTake it forward
Organize a conversation with a qualified professional without creating a treatment recommendation, dose, or protocol.
Organize an existing plan
PeptideGrid can help you organize a schedule and keep dose records together for a plan you already follow. It does not recommend a dose, schedule, or treatment.
Trace the record
Each source supports the section that cites it; publication does not imply endorsement or suitability.
GENOTROPIN prescribing information
DailyMed. GENOTROPIN (somatropin) prescribing information. Revised May 2026.
National Library of Medicine / Pfizer · Published May 4, 2026 · Accessed Jul 22, 2026 · Prescribing information
Open sourceIdentity, human evidence, laboratory and animal findings, risks, uncertainty, and U.S. product status are shown separately. Missing information stays marked as unpublished instead of being inferred.
